As of 11:19 on March 6, 2025, the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) rose 1.34%, the constituent stock Gushengtang (02273) rose 7.20%, XtalPi-P (02228) rose 6.54%, Lifetech Technology (01302) rose 5.70%, JD Health (06618), Hygeia Medical (06078) and other stocks followed suit. Hong Kong stock pharmaceutical ETF (159718) rose 1.77%, hitting three consecutive gains. The latest price is 0.69 yuan, and the intraday turnover has reached 37.6826 million yuan, with a turnover rate of 15.84%, and the market is active.

As of 11:18 on March 6, 2025, the CSI Pharmaceutical and Medical Device Innovation Index (931484) rose 1.15%, the constituent stocks Yirui Technology (688301) rose 4.41%, WuXi AppTec (603259) rose 3.89%, Allist (688578) rose 3.36%, Haisco (002653), Pharmaron (300759) and other stocks followed suit. Medical Innovation ETF (516820) rose 1.19%, the latest price was 0.34 yuan, and the intraday turnover has reached 32.7062 million yuan, with a turnover rate of 1.84%.

In the long run, as of March 5, 2025, Hong Kong stock pharmaceutical ETFs have risen by 2.42% in the past two weeks. The medical innovation ETF has risen 4.66% in the past 1 month.

In terms of scale, the latest scale of medical innovation ETF reached 1.761 billion yuan. In terms of shares, the latest share of medical innovation ETF reached 5.225 billion shares, a new high in nearly one year.

In terms of capital inflow, Hong Kong stock pharmaceutical ETFs have attracted a total of 16.9655 million yuan in the past 10 trading days. The latest net inflow of medical innovation ETF was 6.7347 million yuan. In the long run, there have been 3 net inflows of funds in the past 5 trading days, with a total of 18.2724 million yuan of "gold absorption", and an average daily net inflow of 3.6545 million yuan.

The data shows that leveraged funds continue to be deployed. The net purchase amount of medical innovation ETF financing reached 1.8975 million yuan on the previous trading day, and the latest financing balance reached 82.8262 million yuan.

During the two sessions of the National People's Political Consultative Conference, Ding Lieming, a member of the National Committee of the Chinese People's Political Consultative Conference (CPPCC) and chairman of Betta Pharmaceuticals, submitted three proposals this year, respectively on stimulating the main role of enterprises in medical science and technology innovation, focusing on the construction of a market-oriented system for the transformation and application of scientific and technological achievements, and enhancing the international competitiveness of China's biomedical industry.

A proposal submitted focuses on how to better stimulate the main role of enterprises in medical science and technology innovation and promote the improvement of industrial innovation capabilities, including improving the price formation mechanism of innovative drugs, exploring the establishment of a diversified medical insurance payment system, specifically supporting collaborative innovation in cutting-edge fields such as stem cell therapy, enhancing the cooperation between government guidance funds and industrial investment funds, jointly supporting the development of innovative drugs, and encouraging mergers and acquisitions. The second proposal focuses on the construction of a market-oriented system for the transformation and application of scientific and technological achievements. The third proposal is to provide suggestions and suggestions on how to enhance the international competitiveness of China's biomedical industry.

The CSI Hong Kong Stock Connect Medical and Health Composite Index selects 50 securities of listed companies in the medical and health industry with good liquidity and large market capitalization from the Hong Kong Stock Connect as index samples to reflect the overall performance of the securities of medical and health listed companies within the scope of Hong Kong Stock Connect.

According to the data, as of February 28, 2025, the top 10 weighted stocks of the CSI Hong Kong Stock Connect Medical and Health Composite Index (930965) are BeiGene (06160), WuXi Biologics (02269), Innovent Biologics (01801), Akeso Biologics (09926), JD Health (06618), CSPC Pharmaceutical Group (01093), Sino Biopharma (01177), Ali Health (00241), Zai Lab (09688), Sinopharm ( 01099), the top 10 weighted stocks accounted for 59.55% of the total.

Hong Kong Pharmaceutical ETF (159718), OTC Connect (Ping An CSI Hong Kong Pharmaceutical ETF Connect A: 019598; Ping An CSI Hong Kong Pharmaceutical ETF Connect C: 019599).

The

CSI Pharmaceutical and Medical Device Innovation Index selects 30 listed companies with good profitability and certain growth and R&D innovation capabilities from the listed companies in the medical and health industry as index samples to reflect the overall performance of the securities of listed pharmaceutical and medical device companies with both profitability and growth.

According to the data, as of February 28, 2025, the top 10 weighted stocks in the CSI Pharmaceutical and Medical Device Innovation Index (931484) are WuXi AppTec (603259), Mindray Medical (300760), Hengrui Pharmaceutical (600276), Aier Ophthalmology (300015), United Imaging Healthcare (688271), Kelun Pharmaceutical (002422), Changchun High-tech (000661), Huadong Medicine (000963), and Zhifei Biotechnology (300122). ), Pharmaron (300759), the top 10 weighted stocks together accounted for 66.9%.